Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
 
 

Antibiotics Prophylaxis for Knee Arthroplasty: Benefits and Problems, 2nd Edition

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Antibiotic Therapy in Infectious Diseases".

Deadline for manuscript submissions: closed (15 September 2024) | Viewed by 1621

Special Issue Editor


E-Mail Website
Guest Editor
Department of Orthopedics and Traumatology, Johannes Kepler University, Linz, Austria
Interests: knee arthroplasy; revision knee arthroplasty; multiligament surgery; knee trauma; periprosthetic infection management
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The success of the Special Issue "Antibiotics Prophylaxis for Knee Arthroplasty: Benefits and Problems" has encouraged us to open a second volume on the same topic.

As a continuation of the Special Issue, this second volume focuses on antibiotic agents and application strategies for antibiotic prophylaxis in primary, revision, and tumor knee arthroplasty. Comparisons of agents, the use of multiple agents, comparisons of differing application lengths, between-center comparisons, differing application pathways, and adverse reactions to prophylaxis are some of the topics of interest. Original research manuscripts, short communications, and reviews are welcome.

Dr. Antonio Klasan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antibiotic prophylaxis
  • knee arthroplasty
  • revision knee arthroplasty
  • adverse antibiotic reactions
  • intravenous antibiotics
  • intraosseous regional application

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 860 KiB  
Article
Vancomycin Elution Kinetics of Four Antibiotic Carriers Used in Orthopaedic Surgery: In Vitro Study over 42 Days
by Maria Anna Smolle, Hana Murtezai, Tobias Niedrist, Florian Amerstorfer, Nina Hörlesberger, Lukas Leitner, Sebastian Martin Klim, Reingard Glehr, Raju Ahluwalia, Andreas Leithner and Mathias Glehr
Antibiotics 2023, 12(11), 1636; https://doi.org/10.3390/antibiotics12111636 - 17 Nov 2023
Viewed by 1364
Abstract
This study aimed to analyse and compare the vancomycin elution kinetics of four biodegradable, osteoconductive antibiotic carriers used in clinical practice within a 42-day in vitro setting. Carriers A and D already contained vancomycin (1.1 g and 0.247 g), whereas carriers B and [...] Read more.
This study aimed to analyse and compare the vancomycin elution kinetics of four biodegradable, osteoconductive antibiotic carriers used in clinical practice within a 42-day in vitro setting. Carriers A and D already contained vancomycin (1.1 g and 0.247 g), whereas carriers B and C were mixed with vancomycin according to the manufacturer’s recommendations (B: 0.83 g and C: 0.305 g). At nine time points, 50% (4.5 mL) of the elution sample was removed and substituted with the same amount of PBS. Probes were analysed with a kinetic microparticle immunoassay. Time-dependent changes in vancomycin concentrations for each carrier and differences between carriers were analysed. Mean initial antibiotic levels were highest for carrier A (37.5 mg/mL) and lowest for carrier B (5.4 mg/mL). We observed time-dependent, strongly negative linear elution kinetics for carriers A (−0.835; p < 0.001), C (−0.793; p < 0.001), and D (−0.853; p < 0.001). Vancomycin concentrations increased from 48 h to 7 d and dropped thereafter in carriers C and D whilst constantly decreasing at any time point for carrier A. Carrier B showed a shallower decrease. Mean antibiotics levels at 42 d were 1.5 mg/mL, 2.6 mg/mL, 0.1 mg/mL, and 0.1 mg/mL for carriers A, B, C, and D. Differences in mean initial and final vancomycin concentrations for carrier A were significantly larger in comparison to C (p = 0.040). A carrier consisting of allogenic bone chips showed the highest vancomycin-to-carrier ratio and the largest elution over the study period. Whilst vancomycin concentrations were still measurable at 42 days for all carriers, carrier A provided a higher drug-to-carrier ratio and a more consistent antibiotic-releasing profile. Full article
Show Figures

Graphical abstract

Back to TopTop